Taisho Pharmaceutical Pabron Gold A (Granules) unlicensed product:, product is labelled to contain dihydrocodeine phosphate that is listed on Schedule I of the CDSA

Product sold without market authorization (DIN) in Canada. Product is labelled to contain dihydrocodeine phosphate that is listed on Schedule I of the Controlled Drugs and Substances Act. Product is labelled to contain guaifenesin, dl-methylephedrine hydrochloride, acetaminophen, chlorpheniramine maleate and caffeine that may pose a risk to health.

Product safety

Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns. Contact the recalling firm if you have any questions about the recall. Report any health product related side effects to Health Canada. Report any other health product safety complaints to Health Canada.

Taisho Pharmaceutical Pabron Gold A (Granules)

RA-75652